FDA expanded access: getting a drug outside a trial

Most investigational cancer drugs reach patients one way. Through a clinical trial.

Sometimes that door is closed. The trial is full. The nearest site is too far. Your labs put you outside the eligibility rules. Or there is no trial at all for your situation.

Expanded access is the other door. Many people call it compassionate use. The FDA describes it as a way for patients with serious or immediately life-threatening diseases or conditions to try investigational medical products when no comparable or satisfactory alternatives exist.

The word investigational is the key. These products have not yet been approved or cleared by the FDA.

This is not a general request line. The FDA lists requirements, and a patient has to meet all of them.

• The patient has a serious or immediately life-threatening disease or condition.
• There is no comparable or satisfactory alternative therapy available.
• The patient is not eligible for enrollment in a clinical trial of the product.
• The potential benefit justifies the potential risks of the treatment.
• Providing the product will not interfere with investigational trials that could support development or approval.

That last point surprises people. The system protects the trials themselves. If pulling drug out for individual patients would undermine the study that could get it approved for everyone, that weighs against the request.

Three parties can start the process. Patients, with the help of their physician. Physicians, on behalf of a patient. And industry sponsors, meaning the companies that make the product.

In practice a doctor is always involved. The paperwork is medical. Someone has to prescribe, administer and monitor the treatment. That is not something a patient can do alone.

Oncology has its own help desk. The FDA Oncology Center of Excellence runs Project Facilitate. It is described as a single point of contact call and information center.

Its purpose is to help oncology healthcare providers and regulatory professionals through the process of submitting an expanded access request for an individual patient. The FDA is honest that the application process can be complex, and this is the group that walks a provider through it.

The page lists a provider line at 240-402-0004 and the address [email protected], with hours of Monday through Friday, 8:00 a.m. to 4:30 p.m. Eastern. Patients and families with general questions are directed to the FDA Division of Drug Information at 301-796-3400 or [email protected]. There is an after-hours emergency line for all medical products at 866-300-4374.

Numbers and hours change. Check the current details on their site before you rely on them.

It can give a real path when the standard list is finished. If there is a promising product and you cannot get into a trial, this is the recognized route to ask for it.

It can be started this week. A physician who is willing can make the call and begin the request. It does not require waiting for a new trial to open.

It can bring the FDA's help to your doctor. Project Facilitate exists precisely because the process is hard to navigate alone.

And it can end the guessing. Even a no is an answer, and it frees you to focus on other options.

It cannot force a company to give you a drug. This is the part that hurts most. The manufacturer decides whether to supply the product. The FDA does not stock drugs and cannot order a company to hand one over.

It cannot promise the treatment works. The FDA says it directly. Investigational products may, or may not, be effective, and they may cause unexpected serious side effects.

It is not a substitute for a trial. The pathway is built for people who cannot enroll, not for people who would rather skip the trial.

It does not guarantee anything about cost. Coverage of an investigational product is its own separate question, and one to ask your team early.

It does not come with a timeline you can count on. Emergency situations move faster than routine ones, but no one can hand you a fixed date.

Talk to your oncologist. Not because it is the polite answer, but because nothing in this pathway can begin without a doctor who agrees to carry the request.

Ask two things plainly. Is there a trial I could still join? And if not, are you willing to look into expanded access for me? Those two sentences move things forward more than any amount of reading.